Christopher Spearman, MD
Ophthalmology · Cranberry Township, PANPI 1609263532
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sight Sciences, Inc. at 55.6% of the total. 2025 is the largest year on record at $35,733, more than ten times the $300 reported in 2019. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 518 payments — averaging $131.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$38K
- Bausch & Lomb Americas Inc.$11K
- Glaukos Corporation$8K
- Alcon$4K
- Tarsus Pharmaceuticals, Inc.$2K
- AbbVie$1K
- plus $3K from 22 others
Across 143 payments — averaging $4131.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$233K
- Oyster Point Pharma, Inc.$181K
- Alcon Research LLC$72K
- Bausch & Lomb Americas Inc.$61K
- AbbVie$23K
- Ivantis, Inc$21K
What the payments were for
- Consulting fees$8,71413%
- Speaking & faculty fees$39,74459%
- Travel & lodging$5,5018%
- Food & beverage$13,84120%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 69 | $37,763 |
| Bausch & Lomb Americas Inc. | 71 | $11,075 |
| Glaukos Corporation | 54 | $8,283 |
| Alcon | 132 | $4,121 |
| Tarsus Pharmaceuticals, Inc. | 15 | $2,003 |
| AbbVie(2 entities) | 61 | $1,441 |
| Novartis | 40 | $468 |
| Alcon Research LLC | 1 | $429 |
| Amgen(2 entities) | 13 | $361 |
| Ivantis, Inc | 7 | $354 |
| Biotissue Holdings Inc. | 11 | $301 |
| NEW World Medical,inc. | 12 | $299 |
| Ocular Therapeutix, Inc. | 4 | $270 |
| Aerie Pharmaceuticals, Inc. | 4 | $157 |
| Sun Pharmaceutical Industries Inc. | 5 | $113 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $107 |
| Thea Pharma Inc. | 3 | $63 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $51 |
| Oyster Point Pharma, Inc. | 2 | $46 |
| Genentech USA, Inc. | 2 | $46 |
| Rxsight Inc | 1 | $29 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Dompe US, Inc. | 1 | $22 |
| Harrow Eye, LLC | 1 | $17 |
| Akorn, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $12 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$36,881
- SION SURGICAL INSTRUMENT$25,143
- enVista MX60 IOL$15,002
- enVista Aspire IOL$6,319
- IC-8 Apthera IOL$3,495
- Centurion$379
- iDose TR$321
- iDoseTR$296
- Hydrus Microstent$263
- XDEMVY$239
- Clareon$233
- DEXTENZA$186
- RESTASIS MULTIDOSE$150
- MIEBO$145
- XIIDRA$145
- LUMIGAN$144
- Prokera$142
- AmnioGraft$142
- AcrySof IQ VIVITY$141
- PanOptix$124
How this compares
$67,900 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 51 | $64,829 |
| LumiganBimatoprost | 78 | $41,498 |
| RestasisCyclosporine | 31 | $40,324 |
| XdemvyLotilaner | 21 | $37,009 |
| Cyclosporine | 54 | $30,134 |
| RocklatanNetarsudil Mesylat/Latanoprost | 50 | $18,900 |
| VyzultaLatanoprostene Bunod | 39 | $17,040 |
| Alphagan PBrimonidine Tartrate | 38 | $13,784 |
| Latanoprost | 649 | $9,282 |
| Restasis MultidoseCyclosporine | 14 | $8,459 |
| Prednisolone Acetate | 191 | $5,740 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $4,281 |
| Brimonidine Tartrate | 47 | $3,599 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $3,433 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 116 | $2,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Restasis Multidose, Combigan | $1,441 | $108,346179 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $11,075 | $81,86990 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $2,003 | $37,00921 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $157 | $18,90050 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Cranberry Township
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
- Brandon AyresBala Cynwyd$929K
- David AlmeidaErie$734K
- Carl RegilloPlymouth Meeting$721K
- Robert NoeckerPittsburgh$632K
- Beeran MeghparaPhiladelphia$496K
- Michael KlufasPlymouth Meeting$393K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.